19 patents currently held
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
37 more records may belong here and await a decision; they are not counted.
The next term ends in Apr 2037. from the record
Of the 12 now held by other companies, 10 name Nevakar Pharmaceuticals Inc. as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2037
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2039 · High confidence
Also notable
Ends Jan 2040 · High confidence
Also notable
Ends Mar 2039 · High confidence
Succinylcholine Prefilled Syringe, Compositions and Methods
US 11,779,535
The most cited patent in this portfolio, cited by 9 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Ephedrine Compositions and Methods
US 10,869,845
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2040.
Epinephrine Compositions and Containers
US 11,071,719
A family of 9 related applications built on the 2021 grant. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Jan 2038 · Medium confidence
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
now held by Nevakar Pharmaceuticals, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for Succinylcholine Prefilled Syringe, Compositions and Methods (US 11,779,535) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Epinephrine Compositions and Containers | 8 in force | to Mar 2039 |
| Succinylcholine Prefilled Syringe, Compositions and Methods | 6 in force | to Feb 2039 |
| Ephedrine Compositions and Methods | 3 in force | to Apr 2040 |
| Fixed Dose Combination Formulations for Treating Pain | 1 in force | to Jan 2039 |
| Acetaminophen Pregabalin Combinations and Methods of Treating Pain | 1 in force | to Apr 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,547,686 | Acetaminophen Pregabalin Combinations and Methods of Treating Pain In force · High confidence | In force | High confidence | |
| US 11,590,094 | Fixed Dose Combination Formulations for Treating Pain In force · High confidence | In force | High confidence | |
| US 10,682,308 | Succinylcholine Prefilled Syringe, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 10,722,453 | Succinylcholine Prefilled Syringe, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 10,722,454 | Succinylcholine Prefilled Syringe, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 10,722,455 | Succinylcholine Prefilled Syringe, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 11,779,535 | Succinylcholine Prefilled Syringe, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 12,194,141 | Succinylcholine Prefilled Syringe, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 10,653,646 | Epinephrine Compositions and Containers In force · High confidence | In force | High confidence | |
| US 11,071,719 | Epinephrine Compositions and Containers In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 12 patents in force now held by others · 2 patents ended · 12 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.